OR WAIT null SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
How have lessons from the pandemic influenced the way companies use technology to perform quality-control procedures?
Preclinical and clinical research is improving ADC development.
Strategizing drug development in the preclinical phase has merit.
Perfusion cell culture gains advantage with PAT tools advancement.
Coating is an alternative to silicone oil as a lubricant. URL for article
Novavax COVID-19 Vaccine Receives EUA in Indonesia
December 02, 2021
Sartorius will invest approximately €270 million (US$305 million) to expand its biopharmaceutical manufacturing activities in South Korea’s biopharm hub.
Timing is everything, and it might be ideal for acceleration of real-time monitoring solutions.
Autologous tumor cells engineered for immune system stimulation can target unique metabolic, genomic, and phenotypic characteristics of cancer cells.
Isolators move into smaller-volume processes, including cell and gene therapy manufacturing.
Defining expectations, such as GMPs, is paramount for sourcing the right biopharmaceutical raw materials.
Confounding signals pose challenges to analytical methods necessary for managing residual impurity removal in biotherapeutic manufacturing.
December 01, 2021
While supply chain disruptions have resulted in many alterations to workplace practices, they have also presented an opportunity to get ahead of changes to the EU’s upcoming revision of Annex 1.
Glycosylation monitoring has been heavily dependent on manual processes, but the automation of sample preparation streamlines the overall workflow.
Partnerships formed during the COVID-19 pandemic have provided a platform for change in assay development and transfers that should continue in the future.
COVID-19 is refocusing calls for new tools and urgent therapeutic responses.
The need for medicines to combat COVID-19 has impacted the way regulatory agencies carry out their operations.
We have broken rules, invented new ones, and engineered stronger institutions and supply chains that will serve us better going forward.